Despite a slight uptick in sales, Nobel Biocare saw a 30.5% drop in net profit for the second quarter of 2010 (end-June 30). The Swiss dental-implant company reported net profit of 19.6 million euros ($25.2 million) for the quarter, down from 28.2 million euros ($36.3 million) for the same quarter in 2009.
"After a slow first quarter, sales momentum has improved gradually in the second quarter," said Domenico Scala, CEO, in a press release. "However, mainly as a result of our geographic mix in Europe and a higher exposure to larger case treatments, we continue to underperform in the market."
Sales for the quarter increased to 155 million euros ($199.5 million) from 153.5 million euros ($197.6 million) for the same quarter a year ago, due primarily to positive currency effects.
"We are on track to build up capacity for our broadened prosthetics range and are seeing an increasing demand," Scala said. "We are confident that our strategy of broadening Nobel Biocare's product and solution portfolio, as well as the measures that have already been taken, will allow us to return to growth."
Copyright © 2010 DrBicuspid.com
